A pilot trial of TMM (thiotepa, mitoxantrone and methotrexate) chemotherapy for metastatic breast cancer.
The maximum tolerated dose for a combination chemotherapy regimen of Thiotepa, Mitoxantrone and Methotrexate (TMM) administered intravenously every three weeks to twelve patients with metastatic breast cancer was: Thiotepa: 15mg/m2, Mitoxantrone: 10mg/m2 and Methotrexate: 30mg/m2. The major toxicities from the combination related to myelosuppression. Partial response was seen in 5 patients, ranging in duration from 1.25 to 10 months. Four out of eight patients who had received prior doxorubicin responded. The results are encouraging and warrant further study of this combination.
Bhardwaj
S
S
Department of Neoplastic Diseases, Derald H. Ruttenberg Cancer Center, Mount Sinai Medical Center, New York.
Holland
J F
JF
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D010865:Pilot Projects; D013852:Thiotepa / Q000008:administration & dosage
D013852:Thiotepa; D008942:Mitoxantrone; D008727:Methotrexate